KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to 0.93.

  • Fulgent Genetics' Equity Ratio rose 77.44% to 0.93 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.93, marking a year-over-year increase of 77.44%. This contributed to the annual value of 0.93 for FY2024, which is 100.33% up from last year.
  • Latest data reveals that Fulgent Genetics reported Equity Ratio of 0.93 as of Q3 2025, which was up 77.44% from 0.93 recorded in Q2 2025.
  • In the past 5 years, Fulgent Genetics' Equity Ratio registered a high of 0.93 during Q1 2025, and its lowest value of 0.8 during Q1 2021.
  • Moreover, its 5-year median value for Equity Ratio was 0.92 (2022), whereas its average is 0.91.
  • Over the last 5 years, Fulgent Genetics' Equity Ratio had its largest YoY gain of 1469.06% in 2021, and its largest YoY loss of 1192.84% in 2021.
  • Quarter analysis of 5 years shows Fulgent Genetics' Equity Ratio stood at 0.91 in 2021, then increased by 0.49% to 0.92 in 2022, then grew by 0.38% to 0.92 in 2023, then grew by 1.0% to 0.93 in 2024, then dropped by 0.21% to 0.93 in 2025.
  • Its Equity Ratio stands at 0.93 for Q3 2025, versus 0.93 for Q2 2025 and 0.93 for Q1 2025.